SynOx Therapeutics
SynOx Therapeutics focuses on developing emactuzumab, a monoclonal antibody targeting CSF-1R, for diffuse tenosynovial giant cell tumors and other conditions. The company is supported by experienced investors with a history in biopharma development.
Domain
synoxtherapeutics.com
Country
IrelandIndustry
BiotechnologyEmployees
1-10
Last Funding
$92.0M
Founded
2019
Tech Stack (22 technologies)
Frequently Asked Questions
What technologies does SynOx Therapeutics use?+
SynOx Therapeutics uses 22 technologies including Cookiebot, reCAPTCHA, Twenty Seventeen.
What industry is SynOx Therapeutics in?+
SynOx Therapeutics operates in the Biotechnology industry.
Where is SynOx Therapeutics based?+
SynOx Therapeutics is headquartered in Ireland.
Explore More
Need this data at scale?
Get ready-to-use datasets: companies, technologies, and tech adoption signals across 3M+ websites.
Browse DatasetsData last updated: June 2026